|
|||||||
Identification of a novel compound heterozygous mutation of the 5 Alpha-Reductase type 2 (SRD5A2) gene in an extreme premature 46, XY male infant
|
Objective: To describe the clinical and biochemical features in a very premature male infant with confirmed 5-alpha reductase type 2 deficiency (SRD5A2). Case Presentation: A 46, XY male infant born at 26 weeks of gestation presented at day of life 1 with micropenis and severe hypospadias. Family history was lacking for consanguinity or genetic diseases. At day of life 3, Endocrine service was consulted for evaluation of ambiguous genitalia. Physical examination revealed a small penile length measured at 1.2 cm (-2.2 SD), penoscrotal hypospadias, bifid scrotum, cryptoorchid testes and blind vaginal pouch. Pelvic ultrasonography confirmed bilateral testicular structures present in the superior aspect of the inguinal canal. No Mullerian structures were identified. Persistently elevated testosterone to dihydrotestosterone (T: DHT) ratio lead to direct sequencing of the SRD5A2 gene using exon specific polymerase chain reaction. DNA comparative studies revealed a novel missense mutation within exon 1 of the first allele, with a G>T change altering codon 69 from Alanine to Serine [Ala69Ser]. A second previously reported G>A base change was detected in exon 4, changing the encoded amino acid Glycine to Serine at codon 196 [p.Gly196Ser] in the other allele. Both mutations are predicted to be functionally significant. Discussion: SRD5A2 catalyzes the conversion of testosterone into DHT. This isoenzyme (type 2) is expressed in high levels in the prostate and other androgen-sensitive tissue. The SRD5A2 is located on chromosome 2, region p23 and is comprised of five exons and four introns (Labrie et al 1992). Various studies have demonstrated that any single base mutation of the SRD5A2 gene may result in reduced enzymatic activity (Andersson et al 1991) and incomplete virilization.A second isoenzyme (SRD5A1 or type 1) with 50% sequence identity also exists. Mutations in the SRD5A2 gene associated with male pseudohermaphroditism were first described by Thigpen et al (1992). At least 50 different mutations in the SRD5A2 gene have been compiled by the Human Gene Mutation Database. Of these reported cases, about 60% were homozygous. Conclusion: We describe a novel missense mutation of the SRD5A2 in an extremely premature, genetically male infant. This mutation underscores the importance of the stability of the gene in order to achieve full enzymatic activity. Early identification allowed timely genetic counseling for the family in addition to providing a framework for future care of the patient. Molecular analysis of the SRD5A2 gene should be pursued in genetic males born with clinical evidence of hypovirilization and abnormal T: DHT ratio regardless of gestational age. Journal/Publication - AACE, April 2010 Return to Doctor's Page
|
|||||
Some other Health Articles from our Library:
|
|||||
|